Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,445.91 +64.56 (+0.77%) Bitcoin USD
63,011.88 +1,515.86 (+2.46%) CMC Crypto 200
1,307.39 -50.62 (-3.73%)
Pfizer Inc. (PFE)
Pre-market:
| Previous close | 27.85 |
| Open | 27.76 |
| Bid | 28.16 x 3000 |
| Ask | 28.18 x 1300 |
| Day's range | 27.32 - 28.25 |
| 52-week range | 25.20 - 40.37 |
| Volume | |
| Avg. volume | 42,707,775 |
| Market cap | 159.685B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.05 |
| Earnings date | 30 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | 1.68 (5.96%) |
| Ex-dividend date | 09 May 2024 |
| 1y target est | 29.19 |
GuruFocus.comDecoding Pfizer Inc (PFE): A Strategic SWOT Insight
Insightful Analysis of Pfizer Inc's Financial Health and Strategic Position
BenzingaSecond Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial
A young patient died due to cardiac arrest after receiving Pfizer Inc’s (NYSE:PFE) experimental gene therapy in a mid-stage trial for Duchenne muscular dystrophy (DMD), the company told in a letter to Parent Project Muscular Dystrophy. The boy was enrolled in Phase 2 DAYLIGHT study studying the treatment in boys at least two years old and under four years old. The patient received the investigational gene therapy, fordadistrogene movaparvovec (PF-06939926), in early 2023. Citing Pfizer, Reuters
Insider MonkeyOPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript
OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript May 7, 2024 OPKO Health, Inc. misses on earnings expectations. Reported EPS is $-0.11577 EPS, expectations were $-0.09. OPKO Health, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and […]
